
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for ... Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5¿-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient's regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0038 | 3.06451612903 | 0.124 | 0.135 | 0.1152 | 4157860 | 0.12635514 | CS |
4 | -0.2922 | -69.5714285714 | 0.42 | 0.4375 | 0.1152 | 3081447 | 0.15381338 | CS |
12 | -0.2472 | -65.92 | 0.375 | 2.11 | 0.1152 | 10851522 | 0.59050923 | CS |
26 | -3.1522 | -96.1036585366 | 3.28 | 6.5 | 0.1152 | 5343035 | 0.91949783 | CS |
52 | -6.8722 | -98.1742857143 | 7 | 21.4 | 0.1152 | 6222847 | 5.26266319 | CS |
156 | -7.8722 | -98.4025 | 8 | 21.4 | 0.1152 | 5790603 | 6.1768375 | CS |
260 | -7.8722 | -98.4025 | 8 | 21.4 | 0.1152 | 5790603 | 6.1768375 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions